000538 Yunnan Baiyao Group Co.,Ltd.
Closed 09-07 15:00:00
50.57
-0.45
-0.88%
High51.01Low50.10Vol9.61M
Open51.01D1 Closing51.02Amplitude1.78%
Mkt Cap90.22BTradable Cap90.22BTotal Shares1.78B
T/O485.00MT/O Rate0.54%Tradable Shares1.78B
P/B2.22ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Yunnan Baiyao Reports H1 Revenue of RMB 21.88 Billion and Proposes Special Cash Dividend of RMB 1.85 Billion
Deep News  ·  09-02
Yunnan Baiyao Reports H1 Revenue of RMB 21.88 Billion and Proposes Special Cash Dividend of RMB 1.85 Billion
Yunnan Baiyao's H1 Attributable Profit Edges Up 2%
MT Newswires Live  ·  08-31
Yunnan Baiyao's H1 Attributable Profit Edges Up 2%
Yunnan Baiyao Group H1 Net Profit up 1.88% Y/Y
Reuters  ·  08-28
Yunnan Baiyao Group H1 Net Profit up 1.88% Y/Y
YNBY International H1 FY26 Profit Attributable to Owners Rises 13.31% to HK$ 2.69 Million; Revenue More than Doubled to HK$ 762.54 Million
Reuters  ·  08-14
YNBY International H1 FY26 Profit Attributable to Owners Rises 13.31% to HK$ 2.69 Million; Revenue More than Doubled to HK$ 762.54 Million
2026 Health Industry Summit Explores Pharmacy Evolution: From Drug Retailers to Community Wellness Hubs
Stock News  ·  08-13
2026 Health Industry Summit Explores Pharmacy Evolution: From Drug Retailers to Community Wellness Hubs
Yunnan Baiyao Group Aims to Strengthen Omnichannel Brand Synergy for Future Growth
Deep News  ·  08-11
Yunnan Baiyao Group Aims to Strengthen Omnichannel Brand Synergy for Future Growth
Yunnan Baiyao Posts Over 5.5 Billion Yuan in Core Series Sales for 2025, Marking 18% Growth
Deep News  ·  08-11
Yunnan Baiyao Posts Over 5.5 Billion Yuan in Core Series Sales for 2025, Marking 18% Growth
YNBY International Schedules Board Meeting to Review Interim Results, Weigh Dividend
Reuters  ·  07-30
YNBY International Schedules Board Meeting to Review Interim Results, Weigh Dividend
YNBY International Files HKEX Next-day Disclosure Return on Share Buyback at HKD 0.28
Reuters  ·  07-09
YNBY International Files HKEX Next-day Disclosure Return on Share Buyback at HKD 0.28
YNBY International Files HKEX Next-day Return Disclosing Share Repurchase at HKD 0.27
Reuters  ·  07-08
YNBY International Files HKEX Next-day Return Disclosing Share Repurchase at HKD 0.27
YNBY International Files HKEX Next-day Disclosure Reporting Share Repurchase
Reuters  ·  07-06
YNBY International Files HKEX Next-day Disclosure Reporting Share Repurchase
YNBY International Files HKEX Next-day Disclosure Return on Share Buyback Cancellation
Reuters  ·  07-02
YNBY International Files HKEX Next-day Disclosure Return on Share Buyback Cancellation
YNBY International Files HKEX Next-day Disclosure Return Reporting Share Buyback at HKD 0.25
Reuters  ·  06-30
YNBY International Files HKEX Next-day Disclosure Return Reporting Share Buyback at HKD 0.25
KJ Logistics Secures Dual Projects with Yunnan Baiyao, Establishing a B2B and B2C Integrated Warehousing and Distribution Benchmark
Stock News  ·  06-30
KJ Logistics Secures Dual Projects with Yunnan Baiyao, Establishing a B2B and B2C Integrated Warehousing and Distribution Benchmark
YNBY International Files Next-day Disclosure Return to HKEX on Share Repurchase at HKD 0.24
Reuters  ·  06-24
YNBY International Files Next-day Disclosure Return to HKEX on Share Repurchase at HKD 0.24
Yunnan Baiyao to Invest 360 Million Yuan in Wuxi Transdermal Drug Delivery Technology Platform
Stock News  ·  06-24
Yunnan Baiyao to Invest 360 Million Yuan in Wuxi Transdermal Drug Delivery Technology Platform
YNBY International files HKEX next-day return disclosing share repurchase at HKD 0.22 each
Reuters  ·  06-22
YNBY International files HKEX next-day return disclosing share repurchase at HKD 0.22 each
YNBY International files HKEX next-day disclosure return on share buyback at HKD 0.22 high
Reuters  ·  06-17
YNBY International files HKEX next-day disclosure return on share buyback at HKD 0.22 high
YNBY International files HKEX next-day disclosure reporting share buyback at HKD 0.21
Reuters  ·  06-12
YNBY International files HKEX next-day disclosure reporting share buyback at HKD 0.21
Yunnan Baiyao Affirms Commitment to Strategic M&A, Enhancing Target Evaluation Capabilities
Deep News  ·  06-04
Yunnan Baiyao Affirms Commitment to Strategic M&A, Enhancing Target Evaluation Capabilities

Introduction

Company Name.
云南白药集团股份有限公司
Industry:
医药制造业
Listing Date:
1993-12-15
Main Business:
　　云南白药集团股份有限公司的主营业务是药品、健康品、中药资源的研发、生产及销售。公司的主要产品是工业产品（自制）、批发零售、农产品。公司第17年上榜财富中文网发布的《财富中国500强排行榜》，位列第366位；入选美国《制药经理人》杂志《全球制药企业50强排行榜》，位列第33位。
Issue price:
3.38